Immune checkpoint therapy (ICT) has dramatically altered clinical outcomes for cancer
patients and conferred durable clinical benefits, including cure in a subset of patients …

Since the first Immune Checkpoint Inhibitor was developed, tumor immunotherapy has
entered a new era, and the response rate and survival rate of many cancers have also been …

Single-cell transcriptomics has broadened our understanding of cellular diversity and gene
expression dynamics in healthy and diseased tissues. Recently, spatial transcriptomics has …

Immunotherapy has changed the treatment landscape for cancer over the past decade.
Inhibitors of the immune checkpoint proteins cytotoxic T lymphocyte antigen (CTLA)-4 …

Immune-checkpoint inhibitors (ICIs) have dramatically changed the management of
advanced cancers. Designed to enhance the antitumour immune response, they can also …

T follicular helper (Tfh) cells provide essential help to B cells for effective antibody-mediated
immune responses. Although the crucial function of these CD4+ T cells in infection and …

Neoadjuvant immune checkpoint blockade (ICB) demonstrates promise in operable
esophageal squamous cell carcinoma (ESCC), but lacks available efficacy biomarkers …

Rheumatoid arthritis (RA) is an autoimmune disease affecting synovial joints where different
CD4+ T cell subsets may contribute to pathology. Here, we perform single cell sequencing …

With immune checkpoint inhibitors (ICIs) becoming the mainstay of treatment for many
cancers, managing their immune-related adverse events (irAEs) has become an important …

Cancer treatment has been advanced with the advent of immune checkpoint inhibitors (ICIs)
exemplified by anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), anti-programmed …